Citi puts Australia's Telix on positive catalyst watch of Zircaix FDA filing
TLX•TLX•TLX•TLX•Citi opened a 90-day positive catalyst watch on Telix Pharmaceuticals, citing an expected resubmission of its kidney cancer imaging agent Zircaix to the FDA by year-end. Citi retained its A$31 price target on Telix's ASX-listed shares.
Citi opened a 90-day positive catalyst watch on Telix Pharmaceuticals, citing an expected resubmission of Zircaix to the U.S. FDA by year-end. The brokerage also said intact FY26 guidance and a good start to the quarter imply modest Q4 growth in prostate-specific membrane antigen sales, and estimated a low-single-digit net pricing decline.
Citi said Telix's newly launched brain cancer imaging drug Pixclara had an early average selling price of $8,900 per dose, higher than expected. The brokerage retained its A$31 price target on Telix's ASX-listed shares.
